The estimated Net Worth of Christine Cournoyer is at least $527 Tisíc dollars as of 12 November 2020. Ms. Cournoyer owns over 2,303 units of Caredx Inc stock worth over $242,990 and over the last 5 years she sold CDNA stock worth over $0. In addition, she makes $283,594 as Independent Director at Caredx Inc.
Sign up
Ms. Cournoyer CDNA stock SEC Form 4 insiders trading
Christine has made over 2 trades of the Caredx Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 2,303 units of CDNA stock worth $22,086 on 12 November 2020.
The largest trade she's ever made was buying 2,833 units of Caredx Inc stock on 10 November 2020 worth over $27,848. On average, Christine trades about 132 units every 0 days since 2019. As of 12 November 2020 she still owns at least 8,517 units of Caredx Inc stock.
You can see the complete history of Ms. Cournoyer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christine Cournoyer biography
Christine M. Cournoyer serves as Independent Director of the Company. From 2012 to 2019, Ms. Cournoyer served as the Chairperson and Chief Executive Officer for N-of-One, Inc., a leading company in precision medicine delivering clinical and molecular decision support for targeted therapies decisions based on a cancer patient’s molecular profile. Prior to joining N-of-One, Ms. Cournoyer was the Vice President of Clinical Analytics at Optum, responsible for clinical electronic health records solutions and clinical decision support solutions. Prior to joining Optum through the acquisition of Picis, Inc. in 2010, Ms. Cournoyer was the President and Chief Operating Officer for Picis, a company in the healthcare IT market offering digital solutions to automate the clinical and revenue cycle workflows for the high acuity operations of hospitals. Prior to Picis, Ms. Cournoyer was responsible for all analytical solutions serving the retail industry at Harte Hanks, Inc. Ms. Cournoyer has also held roles at Lotus and IBM. At Lotus she was the Chief Information Officer. At IBM she was Vice President of Global Business Transformation, responsible for driving the digital strategy for global software fulfillment for the $8B software business. Ms. Cournoyer has served on a variety of boards over the last 20 years, including The Stride Rite Corporation, GTECH Corporation, BJ’s Wholesale Club, Inc. and Emerson Hospital. Ms. Cournoyer holds a B.S in Business Administration from University of Massachusetts, an M.A. in Economics from Northeastern University and has attended MIT’s Executive Education Program.
What is the salary of Christine Cournoyer?
As the Independent Director of Caredx Inc, the total compensation of Christine Cournoyer at Caredx Inc is $283,594. There are 10 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of $8,855,740.
How old is Christine Cournoyer?
Christine Cournoyer is 68, she's been the Independent Director of Caredx Inc since 2019. There are 1 older and 15 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
What's Christine Cournoyer's mailing address?
Christine's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.
Insiders trading at Caredx Inc
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon a Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
What does Caredx Inc do?
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
What does Caredx Inc's logo look like?
Complete history of Ms. Cournoyer stock trades at Caredx Inc a Spok Inc
Caredx Inc executives and stock owners
Caredx Inc executives and other stock owners filed with the SEC include:
-
Peter Maag,
Executive Chairman of the Board of Directors -
Michael Bell,
Chief Financial Officer -
Reginald Seeto,
President, Chief Executive Officer, Director -
Dr. Peter Maag Ph.D.,
Exec. Director -
Sasha King,
Chief Marketing Officer -
Alexander L. Johnson,
Pres of Patient and Testing Services -
Sasha King M.B.A.,
Chief Marketing Officer & Franchise Head of Kidney Transplant -
Marcel Konrad,
Sr. VP of Fin. and Accounting & Corp. Controller -
Michael Goldberg,
Lead Independent Director -
Grace Colon,
Independent Director -
Christine Cournoyer,
Independent Director -
Ralph Snyderman,
Independent Director -
George Bickerstaff,
Independent Director -
Frederick Cohen,
Independent Director -
William Hagstrom,
Independent Director -
David Clair,
IR Contact Officer -
Marica Grskovic Ph.D.,
Chief Operating Officer -
Abhishek Jain,
CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer -
Dr. Mickey Y. Kim M.D.,
Sr. VP of Corp. Devel. & Strategy -
Abraham Ronai Esq.,
Gen. Counsel, Chief Admin. & Legal Officer and Sec. -
Ian Cooney,
VP of Investor Relations -
Amitabh Shukla,
Sr. VP of Technology -
Paul Ciccolella,
Sr. VP of Global Operations -
Ankur Dhingra,
Chief Financial Officer -
Charles Constanti,
Chief Financial Officer -
Douglas S Miller,
Director -
Todd Whitson,
Chief Commercial Officer -
Brook H Byers,
Director -
John Joseph Sninsky,
Chief Scientific Officer -
James P Yee,
Chief Medical Officer -
Neil Gagnon,
10% owner -
Mitchell J Nelles,
Chief Operating Officer -
Anders Karlsson,
See Remarks -
Richard Bryan Riggsbee,
Director -
Amy Abernethy,
Director -
Fred E Cohen,
-
Ken Ludlum,
Chief Financial officer -
Matthew J. Meyer,
Chief Business Officer -
Joshua De Fonzo,
Chief Commercial Officer -
Perkins Caufield & Byers X ...,
-
Group Holdings (Sbs) Adviso...,
-
Abraham Ronai,
See Remarks -
Abhishek Jain,
Chief Financial Officer -
Ankur Dhingra,
Chief Financial Officer -
Hannah Valantine,
-
Arthur A Torres,
-
Alexander L Johnson,
See Remarks -
Jeffrey Adam Novack,
Secretary and General Counsel